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Abstract
Cancer cells often depend on microenvironment signals from molecules such as cy-
tokines for proliferation and metabolic adaptations. PRL-3, a cytokine-induced onco-
genic phosphatase, is highly expressed in multiple myeloma cells and associated with 
poor outcome in this cancer. We studied whether PRL-3 influences metabolism. Cells 
transduced to express PRL-3 had higher aerobic glycolytic rate, oxidative phospho-
rylation, and ATP production than the control cells. PRL-3 promoted glucose uptake 
and lactate excretion, enhanced the levels of proteins regulating glycolysis and en-
zymes in the serine/glycine synthesis pathway, a side branch of glycolysis. Moreover, 
mRNAs for these proteins correlated with PRL-3 expression in primary patient my-
eloma cells. Glycine decarboxylase (GLDC) was the most significantly induced me-
tabolism gene. Forced GLDC downregulation partly counteracted PRL-3-induced 
aerobic glycolysis, indicating GLDC involvement in a PRL-3-driven Warburg effect. 
AMPK, HIF-1α, and c-Myc, important metabolic regulators in cancer cells, were not 
mediators of PRL-3’s metabolic effects. A phosphatase-dead PRL-3 mutant, C104S, 
promoted many of the metabolic changes induced by wild-type PRL-3, arguing that 
important metabolic effects of PRL-3 are independent of its phosphatase activity. 
Through this study, PRL-3 emerges as one of the key mediators of metabolic adapta-
tions in multiple myeloma.
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1 |  INTRODUCTION
PRL-3, a phosphatase encoded by the gene PTP4A3, is 
ectopically expressed in many cancers, particularly in 
metastatic tumors.1 This was first observed in several car-
cinomas,2-6 and later in hematopoietic cancers like multi-
ple myeloma (MM), leukemia, and lymphoma.7-13 PRL-3 is 
regulating magnesium homeostasis14-17 and a series of cell 
signaling events.18
MM, the cancer of plasma cells, occurs mainly in the 
bone marrow. Despite several new treatment options in recent 
years, it is still considered an incurable disease. MM cells 
are dependent on signals from the microenvironment, and the 
cytokine interleukin (IL)-6 is one of the molecules allowing 
them to survive and proliferate.19,20 Growth factor signals 
are critical not only for cell proliferation, but also for import 
and processing of nutrients.21 Metabolic adaptations are not 
merely an intrinsic response to the proliferative stimulus but 
also regulated by external signals that can be separated from 
the proliferative signal.22
PRL-3 is highly expressed in MM cells in a large pro-
portion of patients7 and correlates strongly with an unfavor-
able prognosis for patients with MM.23,24 We have previously 
shown that PRL-3 is induced in MM cells by growth factors 
such as IL-6,7,25 and that PRL-3 protects cells against apop-
tosis without contributing to proliferation. This is mediated 
by the oncoprotein Src and stabilization of the anti-apoptotic 
protein MCL-1.25,26 As there is a complex interplay between 
metabolism, proliferation, and cell death, we wanted to ex-
amine whether PRL-3 regulates the metabolic adaptation of 
cancer cells.
2 |  MATERIALS AND METHODS
2.1 | Cell culture
All cells were grown in RPMI-1640 supplemented with 0.68 
mM of L-glutamine and 10%-20% heat-inactivated fetal 
calf serum (FCS). INA-6 was cultured in media with 1 ng/
mL of IL-6. Cells were cultured at 37°C in a humidified at-
mosphere with 5% CO2 and growth media were replenished 
twice weekly. Human myeloma cell lines INA-6 and JJN-3 
were a gift from Dr. M. Gramatzki, University of Erlangen-
Nurnberg, Germany and Dr. I.M. Franklin, University of 
Birmingham, UK, respectively. Human Hodgkin’s lymphoma 
cell line L1236 (ACC 530) was from DSMZ (Brauschweig, 
Germany) and human B-ALL cell line Reh from ATCC 
(Rockville, MD). Cells were cultured as described previ-
ously.8,9,25 New cultures of cells were seeded at least every 
4 months from vials aliquoted with cells propagated shortly 
after receiving the cells from their described original source, 
and they were regularly tested to ensure absence of myco-
plasma. For hypoxic conditions cells were kept in an incu-
bator with 2% O2. In order to deplete cells of IL-6 before 
experiments, they were washed three times with Hanks' bal-
anced salt solution (HBSS) (Sigma-Aldrich, St. Louis, MO). 
When glucose starvation was performed, cells were grown in 
glucose-free RPMI-1640 Medium (Thermo Fisher Scientific, 
MA) and in conditions where serine and/or glycine were de-
pleted, MEM medium (Cat No#21090022, Thermo Fisher 
Scientific) was used.
2.2 | Antibodies, cytokines, and 
other reagents
IL-6 was from Biosource (Camarillo, CA). PRL-3 inhibi-
tor I (5-[[5-Bromo-2-[(2-bromophenyl)methoxy]phenyl]
methylene]-2-thioxo-4-thiazolidinone) was from Sigma-
Aldrich. Thienopyridone was a gift from Professor John S. 
Lazo (University of Virginia, Charlottesville, VA). Serine 
(S4500) and glycine (104201) were purchased from Sigma-
Aldrich and Millipore, respectively.
PBMN-ires-GFP was a gift from Garry Nolan (Addgene 
130 plasmid # 1736), pLKO and shRNA-pLKO against 
PRL-3 were a gift from Dr. Jim Lambert (University of 
Colorado, Denver, CO). pLenti CMV Puro DEST (w118-1) 
was a gift from Eric Campeau & Paul Kaufman (Addgene 
plasmid # 17452).27
Antibodies against β-Tubulin (#2146), hexokinase II 
(#2867), GLUT1 (#12939), SHMT2 (#12762), PHGDH 
(#66350), β-actin (#4967), MTHFD2 (#41377), Phospho-
AMPKα (Thr172) (#2535), LDHA (#3582), c-Myc 
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(#5605), PGAM1 (#12098), Aldolase A (#8060), and 
AMPKα (#5832) were purchased from Cell Signaling 
Technology (BioNordika AS, Oslo, Norway). Antibodies 
against CD98 (#sc-376815), PRL-3 (318) (#sc-130355), 
GLDC (#sc-376196), and PSPH (#sc-271421) were pur-
chased from Santa Cruz Biotechnology (Dallas, TX). 
Antibodies against HIF-1 alpha (#AF1935), PSAT1 (#PA5-
22124), GCAT [EPR13450]—N-terminal (#ab181094), 
and GPI (#HPA024305) were purchased from R&D sys-
tems (Minneapolis, MN), Invitrogen (Waltham, MA), 
Abcam (Cambridge, UK) and Sigma-Aldrich, respectively. 
All siRNAs used were ON-TARGETplus siRNAs from 
Dharmacon (Lafayette, CO) : against GLDC (J-009305-06-
0002, J-009305-07-0002, J-009305-08-0002, J-009305-
09-0002, LU-009305-00-0002), against AMPKα1 
(J-005027-06-0002, J-005027-06-0002, against AMPKα2 
(J-005361-07-0002, J-005361-06-0002), and control 
siRNA (D-001810-10-05).
2.3 | Viral transduction
PRL-3 in JJN-3 cells was expressed by lentiviral transduc-
tion as described previously.8,9 pLenti CMV Puro DEST- 
PTP4A3 or pLenti CMV Puro DEST (Control plasmid) was 
used to establish PRL-3-JJN-3 and Mock-JJN-3. Transduced 
cells were grown in medium containing 0.2 μg/ml of puro-
mycin for selection. PRL-3 in L1236 and Reh cells was sta-
bly knocked down by lentiviral transduction as described 
previously.8,9
PRL-3 was overexpressed in INA-6 by retroviral transduc-
tion as previously described.26 Cells were cloned by limiting 
dilution to yield individual clones followed by the analysis of 
PRL-3 protein levels.
2.4 | Nucleofection
Gene knockdown by siRNA was performed as described pre-
viously25 using Amaxa Cell Line Nucleofector Kit R, [Lonza, 
Switzerland]). Briefly, cells in transfection buffer were added 
to separate nucleofection cuvettes containing 1 μM of four in-
dividual siRNAs and transfected by a Nucleofector II device 
(Lonza) (program X-001 and T-001 were used for INA-6 and 
JJN3, respectively).
2.5 | Immunoblotting
Cells were treated as indicated and collected, lysed and 
immunoblotting was performed as described previously.25 
Images were acquired using LI-COR Odyssey Fc and ana-
lyzed with Image Studio Software (LI-COR, Lincoln, NE).
2.6 | Relative ATP measurement
Level of cellular ATP production was estimated using CTG 
Cell Viability Assay (Promega, Fitchburg, WI) as described 
previously.26
2.7 | Cell viability
Apoptosis was evaluated using Annexin V-Alexa Fluor 
647 binding (A23204, Thermo Fisher, MA), as previously 
described.25
2.8 | Glutathione (GSH) levels
GSH levels were measured using the GSH-GLO Assay 
(Promega) according to the manufacturer’s instructions. 
Briefly, 20  000 cells were seeded in 25  µL of PBS per 
well. Reagents were added according to the protocol from 
Promega, and the luminescent signal was detected by Victor3 
plate reader (PerkinElmer, CT) with Wallac 1420 Work 
Station software.
2.9 | Glycolytic flux
Glycolysis and oxidative phosphorylation (OXPHOS) in 
cells were measured using Glycolysis stress and Cell Mito 
Stress test kits in Seahorse XF96 bioanalyzer (Seahorse 
Bioscience, North Billerica, MA) according to the manu-
facturer’s instructions. Briefly, 96-well Seahorse cell cul-
ture plates were coated with cell-tak in advance and 25 000 
viable cells were cultured per well on day of experiment. 
To hydrate a sensor cartridge, 200 µL of distilled sterile 
water was added to each well of the XF Utility Plate. The 
XF Sensor Cartridge was placed on top of the utility plate 
and incubated overnight in 37°C without CO2. 45-60 min-
utes before experiment, water was replaced with Seahorse 
Calibrant solution. On the day of experiment, assay me-
dium was prepared by supplementing Seahorse XF Base 
Medium (102353-100, Seahorse Bioscience) with 2 mM 
of glutamine, warming it up to 37°C and setting the pH 
to 7.4 with 0.1 N NaOH. A total of 25  000 cells/50 µL 
of assay media was seeded per well and incubated for ap-
proximately 30 minutes in 37°C incubator without CO2 to 
ensure that the cells had completely attached. A total of 
130 µL of warm assay medium was added gently along the 
side of each well to get the final volume of 180 µL.
We used the constant compound concentration with vari-
able loading volume approach.
For Glycolysis Stress test, glucose (G7021, Sigma-
Aldrich), oligomycin (O4876, Sigma-Aldrich), and 
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2-deoxy-D-glucose (D8375, Sigma-Aldrich) were loaded into 
ports A, B, and C of a hydrated sensor cartridge. Final con-
centration used for glucose, oligomycin, and 2-deoxy-D-gly-
ucose was 10 mM, 1 µM, and 50 µM, respectively.
For the Cell Mito Stress test kit the Seahorse XF Base 
Medium was supplemented with 2 mM of glutamine, 10 
mM of Na-Pyruvate (p5280, Sigma-Aldrich) and glucose. 
Ports A, B, and C were loaded with oligomycin, FCCP 
(C2920, Sigma-Aldrich), and Antimycin/Rotenone (A8674 
and R8875, Sigma-Aldrich), respectively. Final concentra-
tion used was 1 μM of oligomycin and FCCP and 2 μM of 
Antimycin/Rotenone.
For measuring glycolysis and OXPHOS a program with 
2-minute mixture, followed by 5-minute measurement after 
each injection was used. Data were analyzed using Agilent 
Seahorse Analyzers Wave 2.6.
2.10 | Quantification of extracellular 
glucose, glutamine, and lactate
Four parallel cultures of PRL-3-INA-6, PRL-3-JJN-3, and 
mock cells were seeded at a density of 4-7 × 105 cells/mL 
with (INA-6) and without (INA-6 and JJN-3) IL-6 and in-
cubated for 24 hours. Fresh and conditioned medium sam-
ples were collected and processed for the quantification of 
extracellular levels of glucose, glutamine, and lactate by nu-
clear magnetic resonance (NMR) as described previously.28 
Consumption and production over 24 hours were normalized 
to average number of live cells in the 24-hour interval to ob-
tain consumption/production /cell/24 hours.
2.11 | Analysis of CoMMpass data
RNA-seq data on purified MM cells from 767 patient sam-
ples were downloaded from the CoMMpass (IA12 release) 
and used for gene expression analysis. The patient samples 
were divided into two different groups based on PRL-3 ex-
pression: 50% High PRL-3 expression vs 50% low PRL-3 
expression. Reactome pathway analysis was performed 
on differentially expressed genes between the two groups 
in the Multiple Myeloma Research Foundation research 
gateway.
2.12 | SILAC-based Quantitative Mass 
Spectrometry
We first cultured cells in Pierce SILAC Protein Quantitation 
Kit—RPMI-1640 (Thermo Fisher). RPMI without L-Lysine 
or L-Arginine was supplemented with 0.68 mM of 
L-glutamine, 40  µg/mL of gentamicin, 10% dialyzed fetal 
bovine serum, and either 100 µg/mL (L-Lysine-2HCl and 
L-Arginine-HCl) or (13C6 L-Lysine-2HCl and L-Arginine-
HCl) to create SILAC-“Light” or SILAC-“Heavy” me-
dium, respectively. Two different clones of PRL-3-INA-6 
(clone 1 and clone 2) and two different clones of mock con-
trol (clone 1 and clone 2) counterparts were grown in both 
SILAC-Heavy and SILAC-Light medium, for a total of seven 
passages before testing the labeling efficiency of the SILAC-
Heavy medium.
Cells were depleted of IL-6 as described above and 
starved for 12 hours in the absence of IL-6. An equal number 
of heavy and light (5 × 105 each) cells were collected and 
lysed in 7 M of urea, 2 M of thiourea, 2.5% of (w/v) CHAPS, 
and 25 mM of DTT for 30 minutes with shaking. Lysates 
were clarified by centrifugation at 16 000 g for 15 minutes 
and proteins in the soluble fractions were precipitated using 
chloroform/methanol as described previously.29 Briefly, 100 
µL of lysate was mixed with 400 µL of methanol, 100 µL of 
chloroform, and 300 µL of water sequentially. The mixture 
was then centrifuged for 2 minutes at 16 000 g. The upper 
layer was discarded and 400 µL of methanol was added to the 
pellet and centrifuged for 2 minutes at 16 000 g. The pellet 
was re-suspended in 150 µL of 50 mM NH4HCO3. To reduce 
disulfide bonds, 7.5 µL of 200 mM DTT was added and the 
mixture was incubated at 70°C for 20 minutes. The reduced 
cysteines were alkylated adding 30 µL of 200 mM iodoacet-
amide and further incubated at room temperature in the dark 
for 30 minutes. Finally, digestion was done at 37°C overnight 
with gentle shaking by adding 1.25 µg of trypsin. The pep-
tides were dried down using SpeedVac before fractionation 
using strong anion exchange combined with C-18 reversed 
phase, SAX in StageTip format and using three different pHs, 
pH-11, pH-6, and pH-3 as described previously.30 After de-
salting, the peptides were dried in a SpeedVac centrifuge and 
resuspended in 0.1% formic acid.
The peptides were analyzed on a LC-MS/MS platform 
consisting of an Easy-nLC 1000 UHPLC system (Thermo 
Scientific/Proxeon) interfaced with an LTQ-Orbitrap Elite 
hybrid mass spectrometer (Thermo Scientific) via a nano-
spray ESI ion source (Proxeon, Odense, Denmark). Peptides 
were injected onto a C-18 trap column (Acclaim PepMap100, 
75 μm i. d. × 2 cm, C18, 5 μm, 100 Å, Thermo Scientific) 
and further separated on a C-18 analytical column (Acclaim 
PepMap100, 75 μm i. d. × 50 cm, C18, 3 μm, 100 Å, Thermo 
Scientific) using a 270-min multistep gradient with buffers 
A: 0.1% formic acid and B: CH3CN, 0.1% formic acid at a 
flow rate of 250 nL/min. 0-252 minutes 0%-30% B, 252-
257 minutes 30%-100% B, 257-262 minutes 100% B, 262-
263 minutes 100%-0% B, and finally 0% B for 7 minutes. 
Peptides eluted were analyzed on the LTQ-Orbitrap Elite 
hybrid mass spectrometer operating in positive ion- and da-
ta-dependent acquisition (DDA) mode using the following 
parameters: Electrospray voltage 1.9 kV, CID fragmentation 
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with normalized collision energy 35, automatic gain control 
(AGC) target value of 1E6 for Orbitrap MS, and 1E3 for MS/
MS scans. Each MS scan (m/z 400-1600) was acquired at 
a resolution of 120  000 FWHM, followed by 20 MS/MS 
scans triggered for intensities above 500, at a maximum ion 
injection time of 200 ms for MS and 50 ms for MS/MS scans.
The raw data files were analyzed using Proteome 
Discoverer Software (Thermo Fisher) mapping the spectra 
over Human proteome downloaded from UniProt.31 Search 
parameters used were as follows: enzyme specified as Trypsin 
with maximum two missed cleavages allowed; Heavy Lysine 
13C (6) + 6.020 Da as variable modification; maximum al-
lowed delta Cn of 0.05; and precursor mass tolerance was 
set to 10 PPM with fragment mass tolerance of 0.6 Da. 
Percolator32 was used to control false discovery rate (FDR) 
for spectra identification and FDR was set to <0.01 (high 
confidence) for selecting peptides used for inferring proteins. 
Median values of uniquely mapped peptide were used for cal-
culating SILAC ratio for each protein.33 These ratios were log 
transformed with base 2 (log2). IDs detected in at least two 
out of three biological replicates were kept for further anal-
ysis. One sided Student’s t test was performed for individual 
time point and P-values were corrected with Benjamini and 
Hochberg algorithm34 using Perseus platform.35
2.13 | 13C NMR of cell extracts
PRL-3-INA-6 and Mock-INA-6 were incubated at 0.8 × 106 
cells/mL for 6 hours in a modified DMEM solution (D9802-
01, US biologicals) containing 2.0 g/L of D-Glucose-1,2-13C2 
(453188, Sigma-Aldrich, USA), 2.0 g/L of sodium bicarbo-
nate, 2.7 mM of glutamine, and 10% heat-inactivated dialyzed 
FBS (Gibco), and without serine and glycine. Approximately 
4 × 107 cells were washed with 50 mL of PBS and spun to a 
pellet (1500 RPM, 8 min) two times. Extraction with 10 mL 
of ice-cold (−20°C) 80:20 methanol/water was performed 
twice. The extracts were vacuum-dried for 20  hours and 
stored at −80°C, before reconstitution in 600 µL of D2O and 
transfer to 5 mm NMR tubes. NMR analysis was performed 
using a 600 MHz Bruker Avance III NMR spectrometer 
(Bruker Biospin GmbH, Germany), equipped with a 5 mm 
QCI Cryoprobe with integrated, cooled preamplifiers for 1H, 
2H, and 13C. Proton spectra were acquired at 300 K using 
1D NOESY (Bruker: noesygppr1d) with presaturation and 
spoiler gradients as previously described.36 The spectra were 
collected with 128 scans and 4 dummy scans. The acquisi-
tion time was 2.73 s and relaxation delay 4 s, measuring the 
free induction decay (FID) via collection of 64 K complex 
data points. Proton decoupled 13C spectra (Bruker: zgpg30) 
were acquired using a power gated coupling sequence with 
a 30º pulse angle as described in Bettum et al.37 The spectra 
were collected with 16 K scans and 16 dummy scans. The 
acquisition time was 1.65 s, relaxation delay 0.5 s, measuring 
the FID via collection of 96 K complex data points over a 
sweep width of 197.175 ppm. The 13C spectra were Fourier-
transformed with a 3.0 Hz exponential line broadening and 
the chemical shift was calibrated to the residual methanol 
signal at 51.4 ppm. Levels of selected metabolites in the ex-
tracts were semiquantitatively assessed by the integration of 
resonance signals using TopSpin 4.0.8 (Bruker Biospin).
2.14 | Statistical analysis
Two-tailed Student’s t test or Mann-Whitney U test was used 
for normally distributed and non-normally distributed data, 
respectively. Correlation coefficients were determined with 
Spearman correlation analysis. The Kaplan-Meier method 
was used for survival analyses, and the survival curves were 
compared with the log-rank test. The statistical analyses were 
performed in GraphPad Prism (version 5.03 or 7.0).
3 |  RESULTS
3.1 | PRL-3 is highly expressed in myeloma 
cells
The IL-6 target PRL-3 protects MM cells against apoptosis 
but does not stimulate proliferation.7 Additional support for 
the importance of PRL-3 in MM was found in gene array 
mRNA data from 917 different cell lines in the Cancer Cell 
Line Encyclopedia38 deposited in the database Oncomine 
(Figure 1A). MM cell lines (n = 26) had on average higher 
expression of the PRL-3 gene (PTP4A3) than all other cancer 
entities. The only comparable entity was leukemia, suggest-
ing that the expression of PRL-3 is of particular importance 
for several cancers of hematopoietic origin.
3.2 | PRL-3 promotes cell growth and ATP 
production but not proliferation
We transduced INA-6 and JJN-3 myeloma cells with an 
empty control vector (Mock-INA-6 and Mock-JJN-3) or an 
expression vector encoding wild-type (WT) PRL-3 (PRL-
3-INA-6 and PRL-3-JJN-3) or mutated enzyme-inactive 
PRL-3 (C104S-INA-6 and C104S-JJN-3). As in our previ-
ous studies of PRL-3 in MM7,25 PRL-3 protected against 
apoptosis without regulating proliferation (Figure  1B). 
However, cells overexpressing PRL-3 had larger cell di-
ameter than mock cells (Figure 1C) indicating that PRL-3 
causes cell growth without stimulating proliferation.
Cells overexpressing PRL-3 also had higher ATP 
level than mock cells (Figure  1D,E). The PRL-3 inhibitor 
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thienopyridone, at a concentration that was not inhibitory to 
cell viability (Figure S1A), reduced ATP production in PRL-
3-INA-6 to the level in Mock-INA-6 (Figure  1D). Finally, 
Hodgkin lymphoma cell line L1236 with stable PRL-3 
knockdown had lower ATP content than L1236 mock cells 
(Figure 1F).
3.3 | PRL-3 increases glycolytic flux and 
oxidative phosphorylation
Since OXPHOS and glycolysis are the major sources 
of ATP, we measured the activity in these metabolic 
pathways. Glycolysis was measured by extracellular acidi-
fication rate (ECAR) with a Seahorse XF analyzer. ECAR 
largely reflects the extracellular lactate concentration, 
which in turn is determined by the rate of glycolysis. PRL-
3-INA-6 and PRL-3-JJN-3 showed higher glycolytic rate 
than their respective mock cells (Figure 2A). The transduc-
tion of INA-6 cells to express PRL-3 was repeated, and 
two individual pairs of clones (PRL-3 and MOCK) from 
this transduction were examined and showed identical re-
sults to those in Figure 2A (data not shown). Both transient 
knockdown of endogenous PRL-3 and thienopyridone 
treatment caused a significant reduction in glycolytic rate 
(Figure 2B,C). However, 8 and 16 μM of thienopyridone 
F I G U R E  1  PRL-3 enhances cell growth and ATP production. A, Expression of PRL-3 mRNA in cell lines from 18 different cancer entities 
in Barretina datasets derived from the public database Oncomine. P-value refers to a t test of the difference between expression in MM cells (n = 
26) and in all other entities combined (n = 891). B, Proliferation was measured in INA-6 and JJN-3 cells using Coulter counter. Plots show mean of 
two independent experiments, each with two replicates. C, Cell diameter was measured in INA-6 and JJN-3 cells using Coulter counter. ATP levels 
measured by the Cell Titer-Glo assay after lysing an identical number of cells in (D) PRL-3 INA-6 and mock cells grown with or without PRL-3 
inhibitor thienopyridone for 4 days, (E) PRL-3 JJN-3 and control mock cells, and (F) shPRL-3 L1236 cells and mock control cells. Plot D shows 
one representative out of two independent experiments, each with five replicates, plot E shows mean of two independent experiments with three 
replicates each, and plot F shows the mean of three independent experiments with minimum four replicates each. Error bars show ± SD. ns, not 
significant, **P ≤ .01, ***P ≤ .001.
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F I G U R E  2  PRL-3 increases glycolysis flux and oxidative phosphorylation. Glycolysis parameters (glycolysis and glycolysis capacity) 
and Oxidative phosphorylation parameters (basal respiration, spare respiratory capacity, proton leak, and ATP production) were measured by 
a Seahorse XF analyzer. Glycolysis in (A) PRL-3-INA-6, PRL-3-JJN-3, and their control mock cells. B, PRL-3-INA-6 and mock cells treated 
with the PRL-3 inhibitor thienopyridone (8 and 16 µM) or DMSO for 24 h before glycolysis measurements. C, Glycolysis in INA-6 cells after 
transient knockdown of PRL-3 by siRNA. Knockdown efficacy is shown by WB. D, Oxidative phosphorylation in PRL-3-INA-6, PRL-3-JJN-3 
MM cells, and their respective mock cells. INA-6 were grown with IL-6. Seahorse graphs show one representative out of at least two independent 
experiments, each with 24 technical replicates. E, Average glucose and glutamine consumption and lactate excretion as well as, lactate/glucose and 
glutamine/glucose ratios were quantified by NMR. Measurements were done in PRL-3-INA-6 and mock cells with and without IL-6, and in PRL-3-
JJN-3 and mock without IL-6. Error bars show ± SD. ns, not significant, ***P ≤ .001
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F I G U R E  3  PRL-3 regulates glycolysis through upregulation of glycolytic enzymes and GLDC. A, Expression levels of selected proteins 
involved in metabolome regulation in PRL-3-INA-6. Dark red and light red indicate higher and lower log2 fold change values, respectively. ND, 
not detected. INA-6 and JJN-3 cells overexpressing wild type (WT) or catalytically dead mutant (C104S) PRL-3, and mock control cells were 
immunoblotted with (B) indicated antibodies and (C) anti-GLDC. INA-6 cells were starved of IL-6 before cell harvest to reduce endogenous 
levels of PRL-3. D, Various MM cell lines were immunoblotted with anti-GLDC and anti-PRL-3. E, PRL-3 INA-6 cells were treated with PRL-3 
inhibitor 1 for indicated time periods and immunoblotted with anti-GLDC and anti-PRL-3. F, GLDC was knocked down in PRL-3-INA-6/JJN-
3 and their control mock cells by transient transfection. Glycolysis was measured 48 h after nucleofection. Protein lysates were prepared from 
the same cells and GLDC protein level was measured by Western blot (left panel). Seahorse graphs are one representative out of at least two 
independent experiments, each with 24 technical replicates. Error bars show ± SD. ns, not significant, ***P ≤ .001
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caused 8.8% and 22.3% reduction in cell viability rela-
tive to the control, respectively (Figure  S1B). Still, the 
magnitude of the change in glycolysis is larger than the 
change in viability. We measured oxygen consumption 
rate (OCR) with the Seahorse XF Cell Mito Stress Test. 
PRL-3-expressing INA-6 and JJN-3 cells had a higher level 
of basal respiration as well as ATP production than mock 
cells. Spare respiratory capacity was only higher in PRL-3-
INA-6 cells than in mock cells (Figure 2D).
To see if PRL-3 regulated glycolysis in other hematopoi-
etic cancers, we measured ECAR in L1236 and the B-ALL 
cell line Reh. In cells with stable knockdown of PRL-3,8,9 
glycolysis, and glycolytic capacity were lower in Reh cells 
(Figure  S2A) and glycolytic capacity was lower in L1236 
cells (Figure S2B) than in the respective mock cells.
3.4 | PRL-3 promotes glucose import and 
lactate export
NMR-based quantification of the main carbon sources (glu-
cose and glutamine) and excretion products in conditioned 
media revealed significantly higher lactate excretion from 
PRL-3-INA-6 and PRL-3-JJN-3 cells than from mock cells 
(Figure  2E), confirming the increased ECAR in Seahorse 
experiments. The high lactate excretion rate was accompa-
nied by increased glucose uptake in both PRL-3-JJN-3 and 
-INA-6, leaving the lactate/glucose ratio equal in PRL-3 and 
mock cells (Figure 2E). The higher consumption of glucose 
combined with higher excretion of lactate suggested an over-
all higher glycolytic flux induced by PRL-3. Notably, PRL-3 
also affected the balance between uptake of glucose and glu-
tamine. The glutamine/glucose ratio was significantly lower 
in PRL-3-INA-6 and PRL-3-JJN-3 cells than in mock cells 
(Figure 2E), indicating that PRL-3 overexpression shifts the 
energy and carbon source preference to glucose at the ex-
pense of glutamine.
3.5 | PRL-3 influences protein expression of 
molecules regulating metabolism
We performed proteome profiling of INA-6 cells with 
SILAC-based quantitative mass spectrometry. In order to 
eliminate the role of IL-6-induced PRL-3, we cultured INA-6 
cells in the absence of IL-6 for 12 h. Figure 3A shows mol-
ecules that are central to cellular metabolism. Here, we ob-
served the upregulation of many enzymes that catalyze the 
glycolytic pathway.
The most conspicuous result of forced PRL-3 expression 
was a marked upregulation of glycine decarboxylase (GLDC) 
protein. Synthesis of serine and further glycine is one of the 
side branches of glycolysis. GLDC decarboxylates glycine, 
thereby transferring carbon into the folate-mediated one-car-
bon metabolism and providing one-carbon units for the pro-
duction of nucleotides and other biomolecules.
In addition, GLDC is a potent regulator of glycolysis.39-42 
We also noticed that transporter molecules and enzymes 
regulating amino acid metabolism (serine/glycine synthesis 
pathway) were influenced by PRL-3 expression.
3.6 | PRL-3-driven glycolysis is influenced 
by glycolytic enzymes and GLDC, but not by 
AMPK, HIF-1α, and c-Myc
The glucose transporter GLUT1 (gene name: SLC2A1), was 
upregulated by PRL-3 in the proteomics analysis (Figure 3A) 
and by Western blotting (WB) in both INA-6 and JJN-3 
(Figure 3B). In INA-6 cells, there was not only an increased 
total amount of GLUT1 in PRL-3 cells, but also a gel mobil-
ity shift, possibly due to the posttranslational modifications 
of GLUT1.
Enzymes catalyzing glycolysis, hexokinase 2 (HK2), glu-
cose-6-phosphate isomerase (GPI), aldolase, triosephosphate 
isomerase (TPI1), phosphoglycerate mutase 1 (PGAM1), 
enolase 1 (ENO1), and lactate dehydrogenase A (LDHA), 
were all found in close to double protein concentrations in 
PRL-3-INA-6 compared to Mock-INA-6 (Figure  3A). But 
of those tested, only HK2 and GPI in INA-6, and LDHA in 
JJN3 were detected at a clearly higher protein level by WB 
(Figure 3B and Figures S3 and S4).
Since GLDC was the enzyme most significantly upregu-
lated by PRL-3 (Figure 3A,C), we wanted to see whether it 
was a mediator of metabolic responses to PRL-3. Publicly 
available data from the Cancer Cell Line Encyclopedia38 
show high expression of GLDC in myeloma cells (Figure S5). 
We detected GLDC protein expression in six out of eight MM 
cell lines, but without clear correlation with PRL-3 expres-
sion (Figure 3D). To confirm that PRL-3 was crucial for the 
upregulation of GLDC, we treated INA-6 cells with PRL-3 
inhibitor 1, which leads to PRL-3 degradation. After 72 
hours, PRL-3 was downregulated and GLDC level decreased 
(Figure 3E). However, we could not exclude the possibility 
that PRL-3 inhibitor I might have off-target effects toward 
other PRL members. Transient knockdown of GLDC reduced 
glycolysis in both PRL-3-INA-6, Mock-INA-6, and in PRL-
3-JJN3, identifying GLDC as another mediator of high gly-
colysis by PRL-3 (Figure 3F).
AMP-activated protein kinase (AMPK), HIF-1α, and 
c-Myc are important regulators of glycolysis.43 Neither 
c-Myc nor HIF-1α contributed to PRL-3-driven glycolysis in 
INA-6 cells (Figure 4A,C). Conversely, there was no increase 
in PRL-3 protein levels in Mock-INA-6 cells cultured in hy-
poxia (Figure 4A). Preincubating cells in hypoxia promoted 
glycolysis in INA-6 cells and weakly in PRL-3-JJN-3 cells. 
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F I G U R E  4  PRL-3-driven glycolysis is not mediated by AMPK, HIF-1α, and c-Myc. A, PRL-3-INA-6, C104S-INA-6, and mock cells grown 
in hypoxia or normoxia for 4 or 24 h and immunoblotted with antibodies against HIF-1α and PRL-3. B, Glycolysis was analyzed in PRL-3-INA-6 
and mock cells grown in hypoxia and normoxia for 4 days. C, PRL-3-INA-6, C104S-INA-6, and mock cells were cultured with serum- and IL-6-
containing medium or in 0.1 % BSA without IL-6 for 4 h and immunoblotted with antibodies against PRL-3, phosph-thr-172 AMPK, total AMPK, 
and c-Myc. D, AMPK was knocked down in PRL-3-INA-6 and mock cells by transient transfection using two different siRNAs against AMPKα1 
and AMPKα2. Glycolysis parameters were measured by Seahorse. E, Protein lysates were prepared from the same cells and AMPKα and PRL-3 
protein level was measured by Western blot. F, PTP4A3 (PRL-3) gene expression is positively correlated with expression of several genes involved 
in glycolysis in MM cells. Spearman correlation coefficients (green) and their respective p-values (blue) between the levels of mRNA for PRL-3 
and glycolysis enzymes, and a few other relevant molecules in 767 samples of purified MM cells from patient bone marrow. Data are derived from 
the CoMMpass study (IA12). Darker green and darker blue indicate higher Spearman correlation coefficient and lower p-value, respectively
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However, also in hypoxia, there was a large difference in gly-
colysis between PRL-3-INA-6 and mock cells (Figure  4B, 
Figure S6). These observations argue against PRL-3 as a me-
diator of HIF-1α-driven glycolysis. Both activation and total 
level of AMPK were reduced in PRL-3-INA-6 (Figure 4C). 
Knockdown of AMPK reduced glycolysis in both PRL-3-
INA-6 and Mock-INA-6 (Figure 4D,E). The observed PRL-3-
induced reduction of AMPK can, therefore, best be explained 
as a negative feedback reaction to the PRL-3-driven increase 
in glycolysis.
Figure 4F shows correlations between expression of the 
PRL-3 gene PTP4A3, a selection of key genes regulating gly-
colysis (c-myc, HIF1α, AMPKα1, and AMPKα2) and genes 
encoding glycolytic enzymes in the CoMMpass MM dataset 
(Interim analysis (IA) 12, n = 767). Interestingly, there was a 
trend for the glycolytic enzymes to have a positive correlation 
with either PTP4A3 or c-myc expression. PTP4A3 correlated 
most significantly with GAPDH, PGK1, PGAM1, and LDHA, 
whereas c-myc correlated with HK2, GPI, PFKM, ENO1, and 
LDHA. This supports that upregulation of enzymes involved 
in glycolysis partly explains higher glycolysis rate in PRL-3-
overexpressing cells.
3.7 | PRL-3 regulates the serine/
glycine pathway
All the enzymes involved in serine synthesis [phosphoglyc-
erate dehydrogenase (PHGDH), phosphoserine aminotrans-
ferase (PSAT1), and phosphoserine phosphatase (PSPH)] 
were expressed in INA-6 and JJN-3, and together with 
methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) 
were more expressed in cells with overexpression of PRL-3 
(Figure 5A, Figure S7, and Figure 3A). MTHFD2 is a mito-
chondrial enzyme that contributes to the synthesis of glycine 
by regenerating the cofactor tetrahydrofolate (THF) needed 
for the serine hydroxymethyl transferase (SHMT)-2 driven 
conversion of serine to glycine.
Another molecule highly upregulated in PRL-3-INA-6, 
particularly after a 12-hour culture without IL-6 (Figures 3A 
and 5A), was the transporter of neutral amino acids, CD98, 
encoded by SLC3A2 and SLC7A5.
In an effort to directly demonstrate the influence of 
PRL-3 on the serine/glycine pathway, we measured the 
level of carbon derived from glucose in serine and glycine 
in PRL-3 and Mock-INA-6 cells by NMR spectroscopy 
F I G U R E  5  PRL-3 regulates serine/glycine synthesis pathway. A, INA-6 and JJN-3 cells overexpressing wild type (WT) or catalytically dead 
mutant (C104S) PRL-3, and mock control cells were immunoblotted with indicated antibodies. INA-6 cells were starved of IL-6 before cell harvest 
to reduce endogenous levels of PRL-3. B, Glycine synthesized from [1,2-13C] glucose (left) and total glycine (right) as measured by NMR. n = 4. 
C, Level of GSH was measured in PRL-3-INA-6, C104S-INA-6, PRL-3-JJN-3 cells, and their respective mock cells. Results are mean of two 
independent experiments each with minimum two replicates. Error bars show SD. ns, not significant, *P ≤ .05, **P ≤ .01, ***P ≤ .001
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after culturing cells without serine and glycine and with 
1,2-13C2-glucose as the only form of glucose. Unfortunately, 
intracellular serine was below the detection limit in both 
PRL-3- and Mock-INA-6. The level of glycine with car-
bon derived from glucose was much higher in Mock-INA-6 
than in PRL-3-INA-6, whereas total glycine content was 
higher in PRL-3-INA-6 (Figure  5B). These results sug-
gest that serine-derived glycine is rapidly degraded by 
GLDC in PRL-3-expressing cells for one-carbon delivery. 
Intracellular [1,2-13C] glucose and [2,3-13C] lactate levels 
were also higher in PRL-3-INA-6, again confirming the in-
creased glycolytic flux (Figure S8).
Consistent with an increased activity in the serine/glycine 
pathway, there were significantly higher levels of GSH, a mol-
ecule dependent on glycine for production, in both INA-6 and 
JJN-3 cells overexpressing PRL-3 than in mock cells (Figure 5C). 
However, we cannot exclude the possibility that increase in GSH 
also could reflect a change in the cells’ redox potential.
F I G U R E  6  Correlation between expression of PRL-3 and serine/glycine pathway enzymes in primary myeloma cells. A, Seven hundred 
and sixty-seven samples of purified MM cells from patient bone marrow from the CoMMpass study (IA12) were divided in two equal groups, 
expressing high or low levels of PRL-3 mRNA. Expression levels of serine/glycine pathway genes in the two groups were compared. B, Kaplan-
Meier plots showing overall survival of patients with high or low expression of enzymes involved in serine/glycine pathway. Data from the 
CoMMpass data bank, IA12
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3.8 | Correlation between expression of 
PRL-3 and serine/glycine pathway enzymes in 
primary myeloma cells
To examine whether PRL-3 expression correlated with expres-
sion of enzymes in the serine/glycine pathway, we dichoto-
mized 767 samples of purified myeloma cells from IA12 of the 
CoMMpass study according to PTP4A3 expression. PHGDH, 
PSAT1, and PSPH, had on average higher expression in samples 
with high levels of PTP4A3. Genes encoding mitochondrial 
enzymes, SHMT2, MTHFD2, and GLDC, showed the same 
pattern, whereas SHMT1 and MTHFD1, cytosolic isoforms of 
these enzymes, showed lower, albeit significant (SHMT1) or no 
covariation (MTHFD1) with PTP4A3 (Figure 6A).
Interestingly, similarly as previously shown for PRL-3 
mRNA,23 high levels of mRNAs for the majority of these en-
zymes predicted reduced overall survival time (Figure 6B). In 
contrast, c-myc mRNA had no prognostic value (Figure S9).
T A B L E  1  Gene set enrichment analysis shows enrichment of genes involved in amino acid metabolism in cells with high PRL-3 mRNA levels
A





1 PTM: gamma carboxylation, hypusine 
formation, and arylsulfatase activation
0.66 2.26 <.0001 30
2 Amino acid and derivative metabolism 0.55 2.24 .022 188
3 Antigen processing-Cross presentation 0.66 2.23 .022 81
4 Regulation of Complement cascade 0.69 2.19 <.0001 23
5 ER-Phagosome pathway 0.71 2.13 .032 64
6 Antigen Presentation: Folding, assembly, and 
peptide loading of class I MHC
0.76 2.12 .022 23
7 Amino acid synthesis and interconversion 
(transamination)
0.89 2.08 <.0001 13
8 Metabolism of steroid hormones and vitamin D 0.61 2.08 <.0001 28
9 Steroid hormones 0.61 2.08 <.0001 28
10 Gamma-carboxylation, transport, and amino-
terminal cleavage of proteins
0.76 2.06 <.0001 13
















Note: Seven hundred and sixty-seven samples from the CoMMpass study of purified MM cells were divided in two groups with high or low levels of PRL-3 mRNA. 
A, A total of 1442 gene sets derived from the Reactome pathway database were analyzed for enrichment in samples with high PRL-3 levels and ranked according to 
normalized enrichment score (NES). Terms related to amino acid synthesis and metabolism are shown in bold. B, Genes in gene set called “Amino acid synthesis and 
interconversion (transamination)” ranked according to fold change in expression between PTP4A3 high and low samples. All the enzymes involved in serine synthesis 
pathway are shown in bold.
Abbreviations: ER, enrichment score; FDR, false discovery rate.
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F I G U R E  7  PRL-3 enables cells to utilize exogenous nutrients and its effect on metabolism is not dependent on PRL-3’s phosphatase activity. 
A, ATP levels were measured using the Cell Titer-Glo (CTG) assay after lysing the same number of PRL-3-INA-6 and mock cells grown in 
various concentrations of glucose for 24 h. The plot shows one representative out of three independent experiments with triplicates. B, Proliferation 
was measured after seeding PRL-3-INA-6 and mock cells overnight with increasing doses of the GLUT1 inhibitor STF-31. The plot is one 
representative out of three independent experiments with three replicates each. C, Proliferation was measured after seeding PRL-3-INA-6 and 
mock cells overnight with indicated serine and glycine concentrations. The plot shows mean of three independent experiments with four replicates 
each. D, Glycolysis was measured by Seahorse XF Analyzer in INA-6 cells overexpressing wild type (PRL-3-INA-6) and catalytically dead PRL-3 
(C104S-PRL-3) and mock control cells. Seahorse graph is one representative out of two independent experiments, each with 24 technical replicates. 
Error bars show ± SD. *P ≤ .05, **P ≤ .01, ***P ≤ .001, ***P ≤ .001, ****P ≤ .0001. E, Schematic illustration of current results. PRL-3, 
mediator of IL-6, promotes the serine/glycine pathway and induces aerobic glycolysis, the latter partly through upregulation of glycolytic enzymes 
and GLDC. Figure is created with BioRender
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Reactome pathway analysis was done for differentially ex-
pressed genes in patients with high versus low PTP4A3 ex-
pression in the CoMMpass cohort. Genes relevant for amino 
acid metabolism had a particularly high normalized enrichment 
score in high PTP4A3 samples. (Table 1A). When the genes 
in “Amino acid synthesis and interconversion (transamination)” 
with 13 genes, were ranked according to fold change, the three 
enzymes involved in serine biosynthesis, PHGDH, PSAT1, and 
PSPH, were the top three genes (Table 1B).
3.9 | PRL-3 enables cells to utilize 
exogenous nutrients but makes INA-6 cells 
vulnerable to GLUT1 inhibition
The PRL-3-mediated increase in glucose- and amino acid 
transporters, suggested that cells with PRL-3 would be bet-
ter prepared to exploit exogenous nutrients. We grew INA-6 
cells without or in the presence of increasing concentration of 
glucose and measured ATP production. In the absence of glu-
cose, there was almost no difference in ATP production be-
tween PRL-3-INA-6 and Mock-INA-6 (Figure 7A). Whereas 
PRL-3-INA-6 showed a glucose-dependent increase in ATP 
production, mock cells apparently were unable to use in-
creased levels of exogenous glucose to enhance their ATP 
production. Interestingly, STF-31, an inhibitor of GLUT1, 
blocked the proliferation of PRL-3-INA-6 much more effi-
ciently than proliferation of the mock cells (Figure 7B).
To see whether PRL-3 enabled cells to utilize exogenous 
serine and glycine, we cultured PRL-3-INA-6 and Mock-
INA-6 in medium with and without glycine and serine and 
measured cell proliferation. Exogenous serine was permis-
sive for increased proliferation of both PRL-3 and mock cells, 
but less so for mock cells. In contrast to serine, glycine did 
not increase proliferation much, neither in the absence, nor in 
the presence of serine (Figure 7C).
3.10 | Non-phosphatase mutant PRL-3 is 
actively regulating glycolysis
In many of the experiments, myeloma cells overexpressing 
a phosphatase-dead mutant of PRL-3 behaved like cells with 
WT PRL-3 (Figures 3B,C and 5A). Consistent data were seen 
in Seahorse experiments (Figure 7D). These experiments in-
dicate that the metabolic switch induced by PRL-3 is not de-
pendent on PRL-3’s phosphatase activity.
4 |  DISCUSSION
Cancer cells can adapt their metabolism to the demands of 
a growing tumor. Increased glycolytic flux and changes in 
amino acid metabolism are central to these alterations.44 
This study adds PRL-3 to the list of important metabolic 
regulators in cancer. PRL-3 stimulated glycolysis and other 
metabolic processes without increasing proliferation, demon-
strating that microenvironment signaling molecules, such as 
IL-6, can alter metabolism via signals that can be separated 
from proliferative signaling. Figure 7E shows an overview of 
the PRL-3 effects described in this paper.
A metabolic switch from OXPHOS to aerobic glycolysis, 
called the Warburg effect, is a cancer hallmark.45 This leads 
to increased production of pyruvate, which in healthy cells 
is oxidized in the TCA cycle to provide reducing power for 
OXPHOS. In cancer cells, pyruvate is typically reduced to 
lactate, supplying carbon units for the synthesis of biomole-
cules required for cell growth.46
In our experiments, PRL-3 potently induced aerobic gly-
colysis, OXPHOS, and thereby, ATP production in hema-
topoietic cancer cells. Upregulation of GLUT1 and CD98, 
transporters for glucose and neutral amino acids, respec-
tively, allowed increased use of exogenous nutrients. PRL-3 
increased import of glucose, but at the cost of making cells 
more dependent on glucose for survival, reflected in the vul-
nerability of PRL-3-expressing INA-6 cells to the GLUT1 in-
hibitor STF-31, a finding that may be of clinical significance.
Enzymes catalyzing glycolysis and the serine/glycine 
pathway, a side path of glycolysis, were upregulated by PRL-
3. Glycine consumption and expression of enzymes in the 
mitochondrial serine/glycine biosynthetic pathway are an-
other important adaptation in cancer metabolism and strongly 
correlated with proliferation rates between different cancer 
cells.47 In contrast to healthy cells, where serine/glycine pro-
duction mostly occurs in cytosol, cancer cells predominately 
produce these amino acids in mitochondria, regulated by en-
zymes only found at low levels in adult tissues.48 In our cells, 
PRL-3 mainly upregulated mitochondrial isoforms of en-
zymes with both a cytosolic and a mitochondrial paralog. We 
found a positive correlation between expression of PTP4A3 
and genes encoding mitochondrial serine/glycine enzymes. 
Enriched expression of serine synthesis pathway genes in 
MM cells from patients with high expression of the PRL-3 
gene, indicates clinical relevance of our cell line findings.
GLDC was the enzyme most upregulated by PRL-3. The 
importance of high levels of GLDC for cancer cells was 
demonstrated in a glioblastoma model.49 If GLDC activity 
was inhibited by shRNA, there was a sharp reduction in cell 
viability, most likely due to conversion of accumulating gly-
cine to toxic metabolites.
Although we cannot completely rule out reduced produc-
tion of glycine, we think high glycine turnover by GLDC ac-
tivity was likely the cause of the low glucose-derived glycine 
content in PRL-3-INA-6 cells after depletion of exogenous 
serine and glycine. Exogenous glycine cannot be used for pro-
duction of one-carbon units but can be converted to serine.50 
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The higher total level of glycine in PRL3-overexpressing cells 
than in mock cells can, therefore, be interpreted as remnants 
of exogenous glycine. The necessity of converting glycine to 
serine is probably lower in PRL-3-expressing cells than in 
mock cells, since the capacity to produce serine from glucose 
is higher than in mock cells.
GLDC is a regulator of glycolysis.39-41 It promotes gly-
colysis in non-small cell lung carcinoma41 and in pluripotent 
stem cells.39 GLDC knockdown in our MM cells gave re-
duced glycolysis, identifying GLDC as one of the mediators 
of PRL-3-driven glycolysis.
Consistent with our findings, in a report by Xu et al., 
PRL-3 promoted glycose uptake and lactate export.51 In col-
orectal cancer cells, they found upregulation of GLUT1 and 
the glycolytic enzymes HK2, PKM2, and LDHA, largely in 
line with our results in MM cells.
Higher ATP production in vitro and increased tumor 
growth in vivo in B16 murine melanoma cells that forcibly 
expressed PRL-3 have been previously reported.52 They 
argue that PRLs bind directly to a membrane protein in-
volved in magnesium homeostasis, CNNMs, which increases 
intracellular Mg2+ levels53 and influences metabolism.14,52 
However, the phosphatase-dead PRL-3 mutant C104S was 
not able to bind CNNM and had no effect on ATP produc-
tion. This contrasts with our experiments where C104S was 
almost as effective as WT PRL-3 in regulating metabolism. 
Since C104S-PRL-3 cannot bind CNNM proteins,16,52 the 
potent influence of C104S on metabolism could be an indi-
cation that PRL-3 does not promote glycolysis and the serine 
synthesis pathway primarily by binding to CNNMs. We were 
not able to pinpoint a specific mechanism for the metabolic 
adaptation in our work. We find it probable that the metabolic 
adaptation observed in the myeloma cells is due to changes 
in the expression or stability of key metabolic proteins. This 
could happen through changes in gene expression, for ex-
ample as the consequence of the direct interaction between 
PRL-3 and histone demethylases as shown by Liu et al.54 and 
Zhang et al.55 or through the activation of transcription fac-
tors such as STAT3, as shown by us and others.23,25
The Warburg effect is promoted when the transcription 
factor HIF-1α is inappropriately stabilized in cells during 
normoxia.43 There was no PRL-3-mediated stabilization 
of HIF-1α in INA-6 cells overexpressing PRL-3, arguing 
against HIF-1α as a downstream mediator of the PRL-3-
driven glycolysis. HIF-1α was strongly induced in INA-6 
cells during hypoxia but was not influenced by PRL-3, and 
PRL-3 was not induced by hypoxia. Overall, this shows that 
hypoxia (HIF-1α) and PRL-3 promote glycolysis by distinct 
mechanisms.
AMPK is another important regulator of cellular metab-
olism.56 PRL-3 reduced activation of AMPK in our cells. 
AMPK is normally activated by cellular stress like depletion 
of nutrients or a low ratio of ATP over AMP/ADP, and it 
promotes catabolic processes.56 AMPK reportedly enhances 
glycolysis in endothelial cells and in rat muscle cells,57,58 
consistent with the reduced glycolytic rate after knockdown 
of AMPK in our study. PRL-3-induced AMPK deactivation 
was most probably the result of a more favorable energy situ-
ation caused by PRL-3 in our cells.
The transcription factor c-Myc, another important regu-
lator of metabolism,43 is often overexpressed in myeloma.59 
We saw no induction of c-Myc by PRL-3 and the CoMMpass 
data did not suggest co-regulation of PTP4A3 and c-myc. 
There was correlation between expression of c-myc and a few 
genes involved in glycolysis, but in general not the genes that 
correlated with PTP4A3 expression. A similar complemen-
tary pattern of correlations was seen for the serine/glycine 
pathway, where c-myc correlated with the genes for two cyto-
solic enzymes, the only two genes that did not correlate with 
PTP4A3 expression (Data not shown).
Even though many phosphatase-dependent functions are 
reported for PRLs,60,61 still an interesting and disputed topic 
in the study of the PRL family of proteins is whether they 
are in fact phosphatases or pseudo-phosphatases in vivo with 
some residual phosphatase activity in vitro. It has been dif-
ficult to convincingly identify direct substrates for PRLs in 
vivo18 and biological effects of PRLs that are not dependent 
on phosphatase activity, have been demonstrated.26,62 In the 
interaction between the PRLs and the magnesium-regulatory 
proteins of the CNNM family, PRLs acts as pseudophospha-
tases.16,63 In the present study, the phosphatase-dead C104S 
mutant PRL-3 was as potent as WT PRL-3 in most of the 
experiments. As an example, phosphatase-dead PRL-3-
stimulated aerobic glycolysis to the same extent as WT PRL-
3. In a previous study, we saw that C104S mutant PRL-3 was 
a weaker (but significant) inhibitor of MM cell apoptosis than 
WT PRL-3, but could not cause phosphorylation of Src.26 
Clearly, a phosphatase-dead PRL-3 mutant has important bi-
ological effects like those of WT PRL-3. The large influence 
of PRL-3 on protein expression could lead to the suspicion 
that it acts as a transcription factor, and this was reported in 
a recent paper.64
In summary, this study establishes a role for PRL-3 as an 
important regulator of metabolism in cancer cells of hemato-
logical origin. Most notably, PRL-3 promotes the serine/gly-
cine pathway and induces aerobic glycolysis, the latter partly 
through upregulation of glycolytic enzymes and GLDC, 
but independently of HIF-1α, c-Myc, and AMPK. PRL-3 
emerges as an attractive target in treatment directed against 
cancer metabolism.
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